AMP-activated protein kinase and pancreatic/duodenal homeobox-1 involved in insulin secretion under high leucine exposure in rat insulinoma beta-cells.
The effect of leucine on glucose-stimulated insulin secretion (GSIS) in pancreatic beta-cells is quite controversial, and mechanism involved in the effect has not been elucidated yet. Consequently, we aimed to investigate effect of leucine on GSIS and its mechanism focusing on contribution of AMP-activated protein kinase (AMPK) and pancreatic/duodenal homeobox-1 (PDX-1). Rat insulinoma beta-cells (INS-1, RIN m5F, DN-PDX-1#28 and PDX-1#6) were cultured with or without leucine, AICAR (AMPK agonist) or compound C (AMPK antagonist) for 48 hrs. In contrast to control, AICAR treatment decreased GSIS at high glucose and insulin content, also impaired protein and mRNA expression of PDX-1 and its downstream targets, glucokinase (GCK) and glucose transporter 2 (GLUT2). Compound C treatment had the opposite effects. We observed that neither AICAR nor compound C could affect expression of GCK and GLUT2 when PDX-1 expression was absent. Chronic leucine exposure inhibited GSIS at high glucose and insulin content in a dose-dependent manner, concomitant with an increase in AMPK and a decrease in PDX-1, GCK and GLUT2. The inhibitory effects of leucine was potentiated by AICAR treatment and rescued by compound C treatment. Finally, the inhibition of PDX-1 could potentiate the impaired effects induced by leucine whereas overexpression of PDX-1 could protect the cell from impairment induced by leucine. The study indicated that chronic leucine might result in an increase in AMPK and then a decrease in PDX-l, in turn to depress GCK and GLUT2 resulting in decreased GSIS at high glucose and insulin content.
Zhang
Xiujuan
X
Department of Endocrinology, Provincial Hospital affiliated to Shandong University, China.
Sun
Nannan
N
Wang
Laicheng
L
Guo
Hua
H
Guan
Qingbo
Q
Cui
Bin
B
Tian
Limin
L
Gao
Ling
L
Zhao
Jiajun
J
D055372:AMP-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005941:Glucokinase / Q000235:genetics / Q000378:metabolism; D051273:Glucose Transporter Type 2; D018398:Homeodomain Proteins / Q000378:metabolism*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D007340:Insulinoma / Q000201:enzymology* / Q000473:pathology; D007930:Leucine / Q000494:pharmacology*; D010190:Pancreatic Neoplasms / Q000201:enzymology* / Q000473:pathology; D051381:Rats; D012265:Ribonucleotides / Q000494:pharmacology; D015534:Trans-Activators / Q000378:metabolism*
D004791:Enzyme Inhibitors; D051273:Glucose Transporter Type 2; D018398:Homeodomain Proteins; D007328:Insulin; D012265:Ribonucleotides; C495683:Slc2a2 protein, rat; D015534:Trans-Activators; C084010:pancreatic and duodenal homeobox 1 protein; D000620:Aminoimidazole Carboxamide; D005941:Glucokinase; D055372:AMP-Activated Protein Kinases; C031143:AICA ribonucleotide; D007930:Leucine